



UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022

March 4, 2022

Conference Call and Webcast Scheduled for Thursday, March 10, 2022, at 10:00 AM ET

PRINCETON, N.J.--(BUSINESS WIRE)--Mar. 4, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2021 financial results on Thursday, March 10, 2022, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

Audio Webcast

The webcast will be made available on the Investors section of the Company's website at <http://investors.urogen.com>. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

Dial-In Information

Live (U.S. / Canada): (855) 765-5685

Live (International): (615) 247-5916

Confirmation number: 7897224

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product Jelmyto (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220304005511/en/): <https://www.businesswire.com/news/home/20220304005511/en/>

INVESTORS:

Vincent Perrone

vincent.perrone@urogen.com

609-460-3588 ext. 1093

MEDIA:

Cindy Romano

Director, Corporate Communications

cindy.romano@urogen.com

609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.